Americans spend more than $4.5 trillion per year on healthcare. That figure, roughly $13,500 per person, is nearly double what the average high-income country spends, and it exceeds the entire gross domestic product of Germany. Yet by almost every measurable health outcome, life expectancy, infant mortality, and chronic disease prevalence, the United States lags behind nations that spend far less.
This is not just an American puzzle. Healthcare costs are rising across the developed world, consuming an ever-larger share of national budgets. In the United Kingdom, NHS waiting lists have surged past 7 million people. In Canada, emergency room wait times regularly exceed 4 hours. Across the OECD, healthcare spending has grown faster than GDP in every decade since the 1970s.
The question is not simply “why is healthcare expensive?” The question is why healthcare markets behave differently from almost every other market in the economy, and what economic theory tells us about the forces driving costs relentlessly upward.
How Healthcare Became the Largest Industry in the World
Healthcare was not always an economic giant. In 1960, the United States spent just 5% of its GDP on healthcare. By 2023, that figure had reached 17.6%, according to the Centers for Medicare and Medicaid Services (CMS). This transformation was driven by three converging forces: technological innovation, demographic change, and the expansion of insurance coverage.
Medical technology has advanced spectacularly over the past six decades. Procedures that were impossible in 1960, such as organ transplants, MRI scans, minimally invasive surgery, and targeted cancer therapies, are now routine. But unlike in most industries, where technological progress drives costs down (think of computers, televisions, or telecommunications), in healthcare, new technology almost always drives costs up. A new cancer drug that extends life by months can cost $100,000 per course. A robotic surgery system costs hospitals $2 million to install. The economic puzzle is that healthcare innovation creates new capabilities, but rarely reduces the price of existing treatments.
Simultaneously, populations across the developed world are ageing. The share of Americans over 65 has risen from 9% in 1960 to 17% today, and it will reach 22% by 2050. Older populations consume far more healthcare: the average American over 65 spends roughly three times as much on medical care as someone between 18 and 44. In Japan, the UK, and Germany, this demographic pressure is even more intense.
The timeline below captures the key milestones that shaped the modern healthcare economy.
The Rise of the Healthcare Economy: Key Milestones
| Year | Event | Economic Significance |
|---|---|---|
| 1965 | Medicare and Medicaid created in the United States | Government becomes the single largest healthcare payer; demand surges overnight |
| 1971 | UK introduces CT scanning (first clinical use at Atkinson Morley Hospital) | Medical imaging revolution begins; diagnostic costs rise sharply |
| 1983 | US introduces Diagnosis-Related Groups (DRGs) for Medicare payments | First major attempt to control costs through fixed-price reimbursement |
| 1990s | Managed care (HMOs) becomes dominant insurance model in the US | Insurers act as gatekeepers; briefly slows cost growth before backlash |
| 2003 | Human Genome Project completed | Opens era of personalised medicine; treatments become more effective but costlier |
| 2010 | Affordable Care Act (ACA) signed into US law | Expands coverage to 20+ million uninsured Americans; insurance markets reformed |
| 2020-2021 | COVID-19 pandemic | Global health spending surges; exposes vulnerabilities in every healthcare system |
| 2023 | US healthcare spending reaches $4.8 trillion (17.6% of GDP) | Healthcare is now the largest industry in the US economy by revenue |
| 2024-2025 | GLP-1 drugs (Ozempic, Wegovy) become blockbusters | Annual cost per patient exceeds $12,000; projected to add $100B+ to global drug spending |
 | ||
Why Healthcare Markets Fail
Healthcare is the textbook case of market failure. Nearly every assumption that makes competitive markets efficient, informed consumers, transparent prices, easy comparison shopping, and freedom to walk away breaks down in healthcare. Four core economic concepts explain why.
The Doctor Knows More Than You
In a normal market, the buyer and seller have roughly comparable information about the product. In healthcare, the information imbalance is extreme. When a cardiologist recommends a bypass surgery, the patient typically cannot evaluate whether the procedure is necessary, whether a cheaper alternative exists, or whether the price being charged is reasonable. This information asymmetry gives healthcare providers enormous market power.
The problem is compounded by a phenomenon economists call supplier-induced demand. Because doctors control both the diagnosis and the treatment recommendation, they can, consciously or unconsciously, generate demand for their own services. Studies in the New England Journal of Medicine have consistently shown that areas with more hospital beds and more specialists per capita have higher rates of surgery and testing, without corresponding improvements in health outcomes. The supply of healthcare, in other words, partly creates its own demand, a phenomenon that violates the standard economic assumption that demand is independent of supply.
Insurance Changes Behaviour
Health insurance is essential. Without it, a serious illness can bankrupt a family. But insurance also distorts economic incentives. When patients pay only a fraction of the true cost of care through copayments and deductibles, they consume more healthcare than they would if they faced the full price. Economists call this moral hazard: the tendency for insurance to increase risk-taking because the insured party does not bear the full cost.
The landmark RAND Health Insurance Experiment, one of the largest and most cited studies in health economics, demonstrated this effect conclusively. Participants who received free healthcare used roughly 30% more medical services than those who paid a share of the cost. Crucially, most of the additional utilisation was for services that had little measurable impact on health outcomes. The extra spending was real, but the extra health benefit was negligible.
On the supply side, fee-for-service payment models create a parallel moral hazard. When hospitals and doctors are paid per procedure, per test, and per consultation, they have a financial incentive to do more, not less. This is the fundamental tension of healthcare economics: the payment system rewards volume rather than value.
The Insurance Death Spiral
Adverse selection is the tendency for people who know they are high-risk to be more likely to buy insurance, while low-risk individuals opt out or buy less coverage. If insurance companies cannot distinguish between healthy and sick applicants, the pool of insured people becomes disproportionately expensive to cover. Premiums rise. As premiums rise, more healthy people drop out, making the pool even sicker. This is the adverse selection death spiral that economists have studied since George Akerlof’s famous “Market for Lemons” paper in 1970.
The Affordable Care Act attempted to solve this problem with two mechanisms: the individual mandate, which required everyone to buy insurance (forcing healthy people into the pool), and community rating, which prevented insurers from charging higher premiums to sick individuals. When the individual mandate penalty was effectively eliminated in 2019, economists warned that adverse selection pressures would return. The evidence is still accumulating, but individual market premiums have risen faster in states with weaker enforcement.
When There Is No Competition
Healthcare markets in many regions are not competitive. Hospital mergers have accelerated dramatically over the past two decades. In 90% of US metropolitan areas, the hospital market is classified as “highly concentrated” by antitrust standards, according to the American Hospital Association. When a hospital system is the dominant provider in a region, it can negotiate higher prices from insurers because the insurer cannot afford to exclude the only major hospital from its network. Research from the National Bureau of Economic Research has found that hospital mergers in concentrated markets lead to price increases of 20% or more with no measurable improvement in care quality.
The pharmaceutical industry operates under even more extreme market power. Patent protection gives drug companies temporary monopolies on new medications. A single drug, Humira, generated $21 billion in revenue in a single year. The GLP-1 drugs Ozempic and Wegovy are projected to generate over $50 billion annually. With no close substitutes and patients whose health depends on continued access, drug companies can set prices that would be impossible in a competitive market. This is textbook monopoly pricing, where price is set far above marginal cost because demand is highly inelastic.
The Numbers That Define Healthcare Economics
The gap between what the United States spends on healthcare and what other wealthy nations spend has widened consistently for half a century. The chart below shows healthcare spending as a percentage of GDP for five major economies since 1970.
Healthcare Spending as a Percentage of GDP (1970-2023)
Source: OECD Health Statistics. US data includes both public and private spending. Other countries are predominantly publicly funded systems.
Despite spending more than any other nation, the United States does not achieve the best health outcomes. The chart below compares per capita health spending with life expectancy across OECD nations, revealing a striking disconnect.
Health Spending Per Capita vs. Life Expectancy (Selected OECD Nations, 2023)
Source: OECD Health Statistics 2023 and World Bank. The US is a clear outlier: highest spending, below-average life expectancy.
The following table breaks down where the money goes in the US healthcare system, revealing the major cost drivers.
Where the Money Goes: US Healthcare Spending by Category (2023)
| Category | Annual Spending | Share of Total | Growth Rate (5-Year Avg.) |
|---|---|---|---|
| Hospital Care | $1.4 trillion | 31% | +5.6% per year |
| Physician & Clinical Services | $884 billion | 19% | +4.3% per year |
| Prescription Drugs | $405 billion | 9% | +7.2% per year |
| Government Administration & Insurance | $338 billion | 7% | +5.0% per year |
| Nursing Care & Retirement Facilities | $204 billion | 4% | +3.8% per year |
| Other (Dental, Home Health, Equipment) | $1.4 trillion | 30% | +4.7% per year |
| |||
The Unequal Impact of Rising Healthcare Costs
The Losers
Uninsured and underinsured Americans bear the most devastating costs. Despite the ACA, approximately 26 million Americans remain without health insurance. For these individuals, a single hospital admission can trigger financial ruin. Medical debt is the leading cause of personal bankruptcy in the United States, affecting an estimated 530,000 families each year, according to the American Journal of Public Health. No other developed nation has this problem at this scale.
Employers and workers face a hidden burden. The average annual premium for employer-sponsored family health insurance in the US reached $23,968 in 2023. While employers pay the majority of this premium directly, economists widely agree that the true cost is borne by workers in the form of lower wages. Healthcare costs that could have been paid as salary are instead absorbed by the insurance system. This is a transfer from workers’ pockets to the healthcare industry that most people never see on their payslip.
Patients in the UK and Canada do not face financial ruin from medical bills, but they pay a different price: time. The NHS waiting list in England exceeded 7.5 million treatment pathways in 2024. In Canada, the Fraser Institute estimated the median wait time from referral to treatment at over 27 weeks. The trade-off between the US and single-payer systems is not quality versus cost alone. It is financial risk versus rationing by time.
The Winners
Pharmaceutical companies are among the most profitable corporations on Earth. The global pharmaceutical market exceeds $1.5 trillion in annual revenue. Profit margins for major drug companies routinely exceed 20%, far above the average for other industries. Patent protection, inelastic demand, and the life-or-death nature of their products give drug makers pricing power that few other industries enjoy.
Health insurers have grown into financial giants. UnitedHealth Group, the largest US health insurer, reported $371 billion in revenue in 2023, making it the highest-revenue company in the Fortune 500 after Walmart. The administrative complexity of the US insurance system, with its billing codes, prior authorisations, and claims processing, generates enormous revenue for an entire ecosystem of intermediaries.
Medical technology innovators benefit from a market where the buyer (the patient) rarely pays the full price, the decision-maker (the doctor) has different incentives from the payer (the insurer or government), and the product is literally a matter of life and death. This combination of insulated demand and emotional urgency creates a market where innovation is handsomely rewarded, regardless of cost-effectiveness.
Can Economics Fix Healthcare?
The fundamental lesson of healthcare economics is that this market is not like other markets. The standard competitive model, where informed buyers shop among competing sellers and prices converge toward the efficient level, simply does not apply. Information is asymmetric, demand is often non-deferrable, and the presence of insurance insulates both consumers and providers from the true cost of their decisions.
Different countries have tried different solutions. The United Kingdom and Canada use single-payer systems where the government acts as the sole buyer of healthcare services, using its monopsony power to negotiate lower prices. Germany and the Netherlands use regulated multi-payer systems where competing insurers operate under strict government rules. Singapore requires citizens to save into personal health accounts, combining individual responsibility with government subsidies. The United States has a hybrid system that combines elements of all these approaches, resulting in the highest spending and the widest coverage gaps in the developed world.
No system has solved the fundamental economic tensions. Every healthcare system faces the same trilemma: you can have any two of universal access, comprehensive quality, and low cost, but achieving all three simultaneously has proven elusive. The economics of healthcare will remain one of the most important and contested domains of applied economics for decades to come, as ageing populations, new technologies, and rising expectations push costs higher across every nation on Earth.
The Economics Behind the Headlines
Conclusion
Healthcare is the world’s largest and most complex industry, and it is growing every year. The economics behind it are unlike any other sector: information asymmetries between doctors and patients, moral hazard from insurance on both sides of the market, adverse selection that destabilises insurance pools, and market power that concentrates pricing authority in the hands of a few dominant players. Together, these forces explain why healthcare costs continue to rise faster than incomes, faster than inflation, and faster than almost any other category of spending in every developed economy.
The central question of healthcare economics is not whether markets or governments should control healthcare. It is how to design institutions, incentive structures, and regulations that align the interests of patients, providers, insurers, and governments in a system where no perfect solution exists. Every country is experimenting. None has found the answer.
Did you find this article helpful? Share it with someone who loves economics. And remember, at MASEconomics, we make complex ideas simple.
